Chloroquine Nasal Drops Have Potential To Prevent Covid-19 Infection In Early Stage: AIIMS Study

Written By : Hina Zahid

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-01-22 09:13 GMT | Update On 2021-01-23 06:49 GMT

New Delhi: A study by the doctors of All India Institute of Medical Sciences (AIIMS), New Delhi reveals that Chloroquine (CQN), when administered as nasal drops, has the potential to prevent COVID-19 infection if administered before the infection is established.

The aim of the study was to explore the safety and efficacy of topical nasal administration of CQN drops in reducing viral load and preventing clinical progression in early COVID-19 infection.

"The present study suggests the potential of topical nasal CQN in the prevention of COVID-19 infection if administered before the infection is established. No significant differences in clinical or virological outcome were, however, demonstrated in patients with mild but established illness," said Dr Alok Thakar, professor at the departments of otorhinolaryngology, Head & Neck Surgery at AIIMS.

The study was an exploratory, randomized controlled trial comparing topical administration of CQN drops in the nose with standard symptomatic management in patients with asymptomatic/mild COVID-19. The study received institutional bio-safety clearance and ethical approval and was registered with the Clinical Trial Registry of India.

The study was conducted at a designated COVID-19 treatment facility (NCI-Jhajjar Campus) at the AIIMS. Study recruitment was from April 23 to May 6, 2020, with a sample size of 60 participants and informed written consent was obtained from all participants.

"RT-PCR tests confirmed asymptomatic patients or those with mild COVID-19 illness were included in the trial. Patients were randomized in a 1:1 manner. Control arm (standard supportive treatment, n=30) was compared with intervention arm (n=30) of a standard treatment plus CQN eye drops (0.03 per cent) repurposed as nasal drops administered six times daily (0.5 ml/dose) for 10 days," noted the study, which is now published in the latest issue of Indian Journal of Medical Science.

The findings stated: "Intranasal CQN (0.03 per cent) was noted as safe and well-tolerated. The clinical outcomes were uniformly good in the subset of patients with mild/ asymptomatic infection. The good clinical outcomes in the control group indicated that a large sample size would be required to demonstrate the effect of any intervention in mild COVID-19 on the basis of clinical outcomes alone."

The present trial did not show any in vivo antiviral efficacy of intranasal CQN drops in patients with mild but established illness, it said. (ANI)

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Chloroquine Nasal Drops Have Potential To Prevent Covid-19 Infection In Early Stage: AIIMS Study

Similar News

AD109 shows positive results for Obstructive sleep apnea in Phase 3 Results

Tezepelumab effective as Add-On Therapy in Both T2-High and T2-Low Severe Asthma: Study

Hearing Devices Significantly Improve Social Lives of Those with Hearing Loss: Study

Higher Dental Radiation Doses Tied to Increased Risk of Cavities in Head and Neck Cancer Patients: Study Finds

Use of Vestibular Suppressants in Seniors with Dizziness Triples Fall Risk, Study Finds

New jab protects babies from serious lung infection, study shows

Allergic Diseases Linked to Reduced Lung Cancer Risk: Meta-Analysis Finds Protective Effect of Allergic Rhinitis

Addressing hearing loss may reduce isolation among the elderly: Study